Benzinga - Gainers
- Crown ElectroKinetics Corp. (NASDAQ: CRKN) shares rose 153% to $0.3325 after gaining 14% on Tuesday. Crown ElectroKinetics, last month, posted a Q3 loss of $0.18 per share.
- Vallon Pharmaceuticals, Inc. (NASDAQ: VLON) shares jumped 140% to $0.6041 after the company entered into a definitive merger agreement with GRI Bio.
- Immix Biopharma, Inc. (NASDAQ: IMMX) jumped 46% to $2.1695 after the company announced it has in-licensed BCMA-targeted next-generation CAR-T therapy NXC-201 with 85% ORR and 71% CR/sCR at the therapeutic dose from the first 20 patients in an ongoing phase 1b relapsed/refractory multiple myeloma ongoing clinical trial.
- Senti Biosciences, Inc. (NASDAQ: SNTI) rose 45% to $2.09 after dipping more than 21% on Tuesday.
- Avidity Biosciences, Inc. (NASDAQ: RNA) shares climbed 44.3% to $15.84 after the company announced AOC 1001 data from the preliminary assessment of the Phase 1/2 MARINA trial demonstrating the first-ever successful targeted delivery of RNA into muscle.
- BIMI International Medical, Inc. (NASDAQ: BIMI) gained 28.1% to $2.6649. BIMI reported entry into a material definitive agreement for the acquisition of Wuzhou Qiangsheng Hospital Co., Ltd., Suzhou Eurasia Hospital Co., Ltd. and Yunan Yuxi Minkang Hospital Co., Ltd.
- Wave Life Sciences Ltd. (NASDAQ: WVE) gained 21.1% to $5.80. SVB Leerink maintained WAVE Life Sciences with a Market Perform and raised the price target from $2 to $7.
- Kymera Therapeutics, Inc. (NASDAQ: KYMR) shares gained 21.4% to $31.38 after the company announced results from the Phase 1 clinical trial evaluating KT-474 in patients with HS and AD and Sanofi (EPA:SASY)'s decision to advance KT-474 into Phase 2 clinical trials.
- Aspen Group, Inc. (NASDAQ: ASPU) gained 17.4% to $0.41 after reporting strong quarterly sales.
- REV Group, Inc. (NYSE: REVG) jumped 17.2% to $15.57 as the company reported a fourth-quarter FY22 sales growth of 5.7% year-over-year to $623.6 million, beating the consensus of $595 million.
- Nuvve Holding Corp. (NASDAQ: NVVE) gained 16.9% to $0.7477.
- Meiwu Technology Company Limited (NASDAQ: WNW) jumped 16.3% to $2.14.
- United Insurance Holdings Corp. (NASDAQ: UIHC) jumped 16.2% to $0.5578.
- Dyne Therapeutics, Inc. (NYSE: DYN) jumped 14.7% to $14.00.
- Sio Gene Therapies Inc. (NASDAQ: SIOX) gained 14.7% to $0.3537.
- Otonomy, Inc. (NASDAQ: OTIC) jumped 14.4% to $0.1399.
- Harmonic Inc. (NASDAQ: HLIT) gained 12.9% to $14.86
- Happiness Development Group Limited (NASDAQ: HAPP) rose 12.9% to $3.9973after surging over 10% on Tuesday.
- Carvana Co. (NYSE: CVNA) gained 12.8% to $5.45.
- Appreciate Holdings, Inc. (NASDAQ: SFR) jumped 12.4% to $1.90.
- Harrow Health, Inc. (NASDAQ: HROW) surged 11.9% to $12.43. Harrow Health entered a binding agreement to acquire the exclusive U.S. commercial rights to five FDA‑approved ophthalmic products from Novartis.
- Mullen Automotive, Inc. (NASDAQ: MULN) jumped 10% to $0.2354. Mullen Automotive partnered with Loop Global to deploy EV charging solutions, including public DC fast charging network and residential offerings.
- QualTek Services Inc. (NASDAQ: QTEK) gained 9.3% to $0.5463.
- Cytokinetics, Incorporated (NASDAQ: CYTK) jumped 7.6% to $41.27. The FDA's Cardiovascular and Renal Drugs Advisory Committee voted 8-3 against the approval of Cytokinetics heart failure drug, omecamtiv mecarbil.
- Processa Pharmaceuticals, Inc. (NASDAQ: PCSA) gained 6.3% to $2.02. Processa Pharmaceuticals said PCS12852 successfully improves the clinical symptoms associated with gastroparesis in Phase 2A trial.
Losers
- Drive Shack Inc. (NYSE: DS) fell 55.3% to $0.2126. The company announced its intention to voluntarily delist from the NYSE and to deregister its common stock.
- ZyVersa Therapeutics Inc (NASDAQ: ZVSA) dipped 36.5% to $4.76.
- Netcapital Inc. (NASDAQ: NCPL) shares dipped 33.3% to $1.47 after the company announced pricing of a public offering.
- OpGen, Inc. (NASDAQ: OPGN) fell 29.8% to $0.1621. OpGen shares jumped around 85% on Tuesday after the company announced topline data from its Unyvero urinary tract infections (UTI) clinical trial.
- Puhui Wealth Investment Management Co., Ltd. (NASDAQ: PHCF) fell 25.7% to $2.95.
- Kaspien Holdings Inc. (NASDAQ: KSPN) fell 24.2% to $0.7490 after the company reported a wider Q3 loss.
- Versus Systems Inc. (NASDAQ: VS) declined 23.1% to $0.5998.
- SeqLL Inc. (NASDAQ: SQL) dropped 21.7% to $0.3789.
- Vincerx Pharma, Inc. (NASDAQ: VINC) declined 21.7% to $0.83.
- Avadel Pharmaceuticals plc (NASDAQ: AVDL) fell 20.9% to $6.52.
- Getaround, Inc. (NYSE: GETR) fell 20.4% to $1.09.
- Bit Brother Limited (NASDAQ: BTB) dropped 20% to $0.4238 after the company announced a 1-for-15 reverse share split.
- Oriental Culture Holding LTD (NASDAQ: OCG) declined 18.8% to $0.71.
- Yumanity Therapeutics, Inc. (NASDAQ: YMTX) fell 16.8% to $1.6886. Yumanity Therapeutics recently declared a special dividend in connection with the proposed asset sale to Janssen and merger with Kineta.
- Baudax Bio, Inc. (NASDAQ: BXRX) fell 16.6% to $2.5925.
- Summit Therapeutics Inc. (NASDAQ: SMMT) fell 16.4% to $3.2691.
- Bright Health Group, Inc. (NYSE: BHG) dropped 16% to $0.6137. Goldman Sachs (NYSE:GS), on Tuesday, downgraded Bright Health from Neutral to Sell.
- Arqit Quantum Inc. (NASDAQ: ARQQ) fell 14.7% to $5.33 after the company reported FY22 results and filed for a mixed shelf of up to $100 million..
- Charter Communications (NASDAQ:CHTR), Inc. (NASDAQ: CHTR) fell 13.3% to $340.65 after it communicated an increase in 2023 capital expenditures at its analyst day held on Tuesday.
- Rubicon Technology, Inc. (NASDAQ: RBCN) shares fell 13.1% to $1.5814. Rubicon Technology announced voluntary delisting from the Nasdaq.
- Nexalin Technology, Inc. (NASDAQ: NXL) fell 11.1% to $1.7250.
- Dragonfly Energy Holdings Corp. (NASDAQ: DFLI) dropped 11% to $12.32.
- LAVA Therapeutics N.V. (NASDAQ: LVTX) fell 9.4% to $4.20. LAVA Therapeutics announced updated data from the Phase 1/2a clinical trial of LAVA-051 at the 64th American Society of Hematology Annual Meeting and Exposition.
- Panbela Therapeutics, Inc. (NASDAQ: PBLA) fell 7.1% to $0.1327 after gaining around 53% on Tuesday. Panbela received EMA opinion on orphan designation for Ivospemin in combination with Gemcitabine and nab-paclitaxel in patients with metastatic pancreatic ductal adenocarcinoma.
Also check this out Bitcoin Tops $18,000; GMX, Dogecoin Among Top Losers.
© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.